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Dear Editor,
The mechanisms involved in chronic myeloid leukemia (CML) 
progression from the chronic phase (CP) to an accelerated phase 
(AP) or blast crisis (BC) remain largely undetermined, but gen-
erally involve additional molecular changes besides the Philadel-
phia chromosome [1]. Evidence suggests that secondary BCR 
(breakpoint cluster region)-ABL1 (Abelson murine leukemia vi-
ral oncogene homolog 1)-dependent/independent genetic events 
play a critical role in blast transformation [2]. Besides BCR-ABL1 
point mutations, deletions and/or rearrangements of other can-
cer-related genes have been associated with CML-BC [2]. Re-
cent studies have demonstrated that aberrant activation-induced 
cytidine deaminase (AID) expression promotes genetic instabil-
ity, eventually leading to progression and drug resistance in CML 
[3].
We report a patient with a rare chromosomal translocation 
46,XY,t(5;12)(p13;p13) that disrupts AID and causes a concom-
itant deletion of the tumor suppressor gene BCL7A (B-cell CLL/
lymphoma 7A). This report presents evidence of a mechanism 
underlying CML progression and tyrosine kinase inhibitor (TKI) 
resistance occurring through an interaction between AID expres-
sion and BCL7A loss in a BCR-ABL1 kinase domain mutation-
independent manner.
A 57-yr-old man presented in December 2010 with general-
ized weakness and chest pain. Bone marrow (BM) demonstrated 
nearly packed marrow owing to myeloid and megakaryocyte hy-
perplasia (blasts [0.4%]). Written informed consent for genetic 
analysis was obtained from the patient according to the ethical 
guidance of the institutional review board. The patient exhibited 
the b3a2 type BCR-ABL1 fusion transcript, and cytogenetic anal-
ysis revealed a normal karyotype. The patient was diagnosed as 
having CML-CP and treated with imatinib (Table 1).
Sixteen months following diagnosis, treatment was replaced 
by dasatinib since BCR-ABL1 transcripts had not declined. Si-
multaneously, one of 25 metaphase cells exhibited an abnormal 
karyotype of 46,XY,t(5;12)(p13;p13) (Fig. 1A). FISH analysis 
using a TEL/AML1 translocation probe presented a normal re-
sult; therefore, another gene on chromosome 12p13 was sus-
pected to be involved. Subsequent FISH analysis revealed a break 
in the AID signal on one allele in 12.2% of interphase cells us-
ing a custom-labeled probe (Empire Genomics LLC, Buffalo, 
NY, USA) (Fig. 1B) compared with 0.2% of normal control cells. 
Quantitative analysis showed that AID RNA expression increased, 
whereas normal cells showed no AID expression.
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Table 1. The clinical course of the patient
Time (months after diagnosis) 0 3 12 16 23 28 29 32 37 38 46
Diagnosis CML-CP CHR - CHR - CML-AP CHR - CML-AP Mixed donor 
chimerism
Complete donor 
chimerism
Karyotype - - - 46,XY,t(5;12)
(p13;p13)
[1]/46,XY[24]
- 46,XY,t(5;12)
(p13;p13)
[5]/46,XY[15]
- - 46,XY,t(5;12)
(p13;p13)
[6]/46,XY[14]
- -
BCR-ABL1 transcript (relative 
ratio of BCR-ABL1 to ABL1)
0.00352 0.08 0.03 0.03 0.3 - 0.09* 0.089 - 0.000223 Negative
Interphase FISH (% of AID 
rearrangement)
- - - 12.2 - - 9.5 - 9.8 - -
AID mRNA expression (relative 
ratio of AID to ACTB)
- - - 3.53 - - 3.23 - 5.32 - -
BCL7A copy number changes Normal - - Deletion - - - - - - -
Treatment Imatinib - - Dasatinib - Nilotinib Imatinib - Allogeneic 
PBSCT
- -
*The real-time PCR method changed from LightCycler t(9;22) Quantification (Roche Molecular Systems, Branchburg, NJ, USA) to Real-Q BCR-ABL1 Quan-
tification (BioSewoom , Seoul, Korea) at the six month follow-up.
Abbreviations: BM, bone marrow; CHR, complete hematologic response; AP, accelerated phase; CP, chronic phase; AID, activation-induced cytidine deami-
nase; PBSCT, peripheral blood stem cell transplantation.
Fig. 1. Genetic analysis of CML-AP BM samples. (A) Translocation site in G-banded karyotyping of the 46,XY,t(5;12)(p13;p13) (arrows). (B) 
Interphase FISH confirming three signals of the AID probe (red), resulting from AID rearrangement at the 12p13 locus. (4,6-diamidino-2-pheny-
lindole stain, ×1,000). (C) Chromosomal microarray revealing copy number loss in the chromosome 12q24.31 region (arrow). Blue dots 
with a log2 transformed value of -1 represent a 1:2 copy number ratio to the reference genomic DNA, indicating a heterozygous deletion. 
The expansion view of the 12q24 region reveals a 1.9-Mb heterozygous interstitial deletion in chromosome 12 (121,949,449-123,968,599; 
hg19) that includes the BCL7A gene.
Abbreviations: AP, accelerated phase; BM, bone marrow; AID, activation-induced cytidine deaminase; BCL7A, B-cell CLL/lymphoma 7A.
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Chromosomal microarray using a CytoScan 750K Array (Af-
fymetrix Inc., Santa Clara, CA, USA) revealed a 1.9-Mb deletion 
mostly containing BCL7A on chromosome 12q24.31 (Fig. 1C).
After 28 months, the patient progressed to CML-AP, and the 
CBC showed leukocyte counts of 116.8×109/L and 13% blasts. 
BCR-ABL1 kinase domain sequencing revealed no mutation. 
Conversely, chromosomal abnormality of t(5;12)(p13;p13) ex-
hibited clonal expansion. Thus, the patient was returned to ima-
tinib therapy and subsequently demonstrated a complete hema-
tologic response; however, AID breakage and BCR-ABL1 tran-
script levels remained detectable.
After 37 months, the patient presented again with CML-AP, 
with 13.5% blasts in peripheral blood, and karyotyping showed 
46,XY,t(5;12)(p13;p13)[6]/46,XY[14]. The patient received allo-
geneic stem cell transplantation and achieved complete donor 
hematopoietic chimerism. 
The AID gene, located on chromosome 12p13, is associated 
with genomic instability and ensuing oncogenesis in various hu-
man malignancies including CML, AML, and ALL [3-5]. AID has 
several non-immunoglobulin targets, including PAX5 and BCL7A 
[3, 6]; PAX5 can induce TKI resistance and CML progression 
via AID upregulation [3].
Recently, it was shown that AID activation can induce muta-
tions and translocations at the BCL7A locus [6]. BCL7A belongs 
to the BCL7 family, which includes BCL7B and BCL7C, and is a 
known pro-apoptotic tumor suppressor in B-cell oncogenesis. 
Specifically, BCL7B suppresses β-catenin expression, causing 
Wnt signaling inhibition [7]. Importantly, β-catenin deregulation 
in Wnt signaling is associated with genomic instability that can 
induce oncogenic translocations in T-cell lymphoma and AML 
[5, 8]. In CML, β-catenin activation is observed in the AP or BC, 
and is believed to promote leukemic stem cell generation that 
facilitates disease progression [9].
We suggest a novel pathway for disease progression and drug 
resistance in CML via AID expression and the concomitant loss 
of BCL7A. Our case supports the hypothesis that BCL7A dele-
tion induces abnormal Wnt/β-catenin signaling, enhancing the 
potential for a chromosomal aberration and its persistence in 
our patient [5, 10]. Loss of the tumor suppressor BCL7A may 
cooperate with AID activity in disease progression by causing 
aberrant cell cycle regulation [1]. Moreover, AID-induced DNA 
damage checkpoint activation causes initiation of tumor sup-
pressor genes involved in DNA repair or cell cycle control [1]. A 
previous study showed that decreased tumor suppressor gene 
expression can cause AID-induced translocation, eventually lead-
ing to cancer [10].
In conclusion, our report identifies that AID, in combination 
with BCL7A, likely confers TKI resistance in a BCR-ABL1 kinase 
domain mutation-independent manner and may be a putative 
functional target in CML therapy. 
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